Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Eduardo Vilar, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of using vaccines for cancer interception, and highlights the Nous-209 vaccine for prevention of mismatch repair deficient pre-cancers and cancers in Lynch Syndrome carriers. Vaccines hold great promise in cancer interception for these populations, offering a potential preventive approach. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.